Clinical Report: Therapeutic Approaches Targeting Gut Microbiota in EORA
Overview
This review highlights the significant role of gut microbiota dysbiosis in elderly-onset rheumatoid arthritis (EORA) and explores therapeutic interventions targeting the gut-joint axis. It emphasizes the interplay between immunosenescence, inflammaging, and gut microbiota in the pathogenesis of EORA.
Background
Elderly-onset rheumatoid arthritis (EORA) poses unique clinical challenges, including increased disease severity and comorbidities compared to younger-onset RA. Understanding the gut-joint connection is crucial as emerging evidence suggests that gut microbiota dysbiosis may contribute to the pathophysiology of EORA. This knowledge can inform targeted therapeutic strategies to improve patient outcomes.
Data Highlights
No numerical data available in the article.
Key Findings
EORA is associated with more refractory disease activity and higher comorbidity burden compared to younger-onset RA.
Immunosenescence and gut microbiota dysbiosis are interconnected factors in the pathogenesis of EORA.
Therapeutic strategies targeting gut microbiota include dietary modifications, nutraceuticals, and fecal microbiota transplantation.
Age-related immune changes significantly influence the clinical presentation and management of EORA.
Current literature on gut microbiota profiles in EORA is limited, indicating a need for further research.
Clinical Implications
Clinicians should consider the role of gut microbiota in managing EORA, particularly when evaluating treatment options. Microbiota-targeted interventions may offer new avenues for improving disease management and patient quality of life.
Conclusion
The interplay between gut microbiota and immune aging presents a promising area for therapeutic exploration in EORA. Further research is essential to fully understand these mechanisms and their implications for clinical practice.
